Sacituzumab Govitecan Toxicity Outcomes In Arab Patients with Metastatic Breast Cancer

被引：0
|
作者：
Altarturi, Maymouna
Suleman, Kausar
AlSayed, Adhar
Al-Shamsi, Humaid
Alawadhi, Aydah
Basuliamn, Bassam
Alaklabi, Sabah
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-12-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-12-10
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Economic Evaluation of Sacituzumab Govitecan for the Treatment of Metastatic Triple-Negative Breast Cancer in China and the US
    Chen, Jigang
    Han, Mingyang
    Liu, Aihua
    Shi, Bo
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] UGT1A1*28 polymorphism and the risk of toxicity and disease progression in patients with breast cancer receiving sacituzumab govitecan
    Wong, Megan H.
    Jones, Veronica C.
    Yu, Wai
    Bosserman, Linda D.
    Lavasani, Sayeh M.
    Patel, Niki
    Sedrak, Mina S.
    Stewart, Daphne B.
    Waisman, James R.
    Yuan, Yuan
    Mortimer, Joanne E.
    CANCER MEDICINE, 2024, 13 (16):
  • [43] A plain language summary of the ASCENT study: Sacituzumab Govitecan for metastatic triple-negative breast cancer
    Bardia, Aditya
    Hurvitz, Sara A.
    Rugo, Hope S.
    Brufsky, Adam
    Cortes, Javier
    Loibl, Sibylle
    Piccart, M.
    Cowden, Janice
    Spears, Patty
    Carey, Lisa A.
    FUTURE ONCOLOGY, 2021, 17 (30) : 3911 - 3924
  • [44] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC)
    Hegewisch-Becker, S.
    Oliveira, M.
    Traina, T.
    Tolaney, S. M.
    Loirat, D.
    Punie, K.
    Hurvitz, S. A.
    Lynce, F.
    Hamilton, E.
    Nanda, R.
    Hart, L.
    Richards, P.
    Malik, Z.
    Rugo, H. S.
    Dieras, V
    Bardia, A.
    Hong, Q.
    Phan, S.
    Itri, L. M.
    Loibl, S.
    Kalinsky, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 242 - 242
  • [45] Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study
    Carrion-Madronal, Isabel Maria
    Diaz-Acedo, Rocio
    Lora-Escobar, Santiago Jose
    Naranjo-Llamas, Eloisa
    Jaramillo-Ruiz, Didiana
    Artacho-Criado, Silvia
    Prado-Mel, Elena
    FUTURE ONCOLOGY, 2024,
  • [46] Sacituzumab govitecan-hziy for triple-negative breast cancer
    Stirrups, Robert
    LANCET ONCOLOGY, 2019, 20 (04): : E194 - E194
  • [47] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Xie, Jiao
    Li, SiNi
    Li, YaMin
    Li, JianHe
    BMC HEALTH SERVICES RESEARCH, 2023, 23 (01)
  • [48] Cost-effectiveness of sacituzumab govitecan versus chemotherapy in patients with relapsed or refractory metastatic triple-negative breast cancer
    Jiao Xie
    SiNi Li
    YaMin Li
    JianHe Li
    BMC Health Services Research, 23
  • [49] Outcomes in patients (pts) aged ≥65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).
    Kalinsky, Kevin
    Oliveira, Mafalda
    Traina, Tiffany A.
    Tolaney, Sara M.
    Loirat, Delphine
    Punie, Kevin
    Hurvitz, Sara A.
    Lynce, Filipa
    Hamilton, Erika P.
    Nanda, Rita
    Hart, Lowell L.
    Richards, Paul D.
    Malik, Zulfiqar A.
    Rugo, Hope S.
    Dieras, Veronique
    Bardia, Aditya
    Hong, Quan
    Olivo, Martin Sebastian
    Itri, Loretta
    Loibl, Sibylle
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] Sacituzumab Govitecan-hziy in Triple-Negative Breast Cancer
    Ozaki, Yukinori
    Masuda, Jun
    Takano, Toshimi
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24): : 2382 - 2382
12345